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A B S T R A C T
Induced pluripotent stem cells (iPSCs) generated from young, healthy individuals are valuable tools for investigating molecular disease mechanisms during the early
development of the brain vasculature. We generated an iPSC line from peripheral blood mononuclear cells (PBMCs) isolated from a healthy 13-yeard old female
donor using the Sendai virus. The iPSCs differentiated into endothelial cells, astrocytes, and neurons. This iPSC line can serve as a healthy reference control for
comparative studies in drug development and modeling the early onset of Cerebral Cavernous Malformation (CCM).
1. Resource Table
Unique stem cell line id-
entifier
UNC001-A
Alternative name(s) of s-
tem cell line
15CA
Institution University of North Carolina
Contact information of
distributor
Adriana S. Beltran (beltran@med.unc.edu)
Type of cell line iPSC
Origin Human





Sendai virus (POU5F1, MYC, KLF4 and SOX2)
Genetic Modification NO
Type of Modification N/A
Associated disease N/A
Gene/locus N/A
Method of modification N/A






Date archived/stock date 7/28/2017
Cell line repository/bank HPSCC (https://www.med.unc.edu/humanstemcellcore/)
Ethical approval The study was approved by the UNC IRB 10-1595. Patient
written informed consent was obtained for blood draw.
2. Resource utility
The iPSC line was derived from PBMCs isolated from a healthy 13-
year old female donor. Erythroblasts were expanded from the PBMCs
and reprogrammed using the integration free Sendai virus. This iPSC
line presents a useful tool that can serve as a control line for com-
parative studies modeling the early onset of Cerebral Cavernous
Malformation (CCM) (Table 1).
3. Resource Details
Cerebral cavernous malformation (CCM) is associated with a wide
range of neurovascular disorders with risky surgery as the only ther-
apeutic intervention available. The onset of CCM stems from the bi-
allelic loss of KRIT1 (CCM1), CCM2, and PDCD10 (CCM3) in the en-
dothelial cells of the brain vasculature (Richardson et al., 2013). Of
these CCM proteins, PDCD10 exhibits an extremely aggressive pheno-
type characterized by an early-onset cerebral hemorrhage, accom-
panied by multiple brain cavernomas, meningiomas, and venous mal-
formations (Riant, 2013). The lack of human cell models has limited not
only the study of the disease, but also the development of therapeutic
efforts.
Here, we generated an iPSCs line from PBMCs isolated from a
healthy 13-year old female donor. Erythroblasts were expanded from
the PBMCs over 14 days and then reprogrammed using the Sendai virus
vector (SeV) encoding the four Yamanaka reprogramming factors:
OCT4, SOX2, KLF4 and c-MYC. After transduction, the erythroblasts
were cultured on inactivated MEFs and after 2 weeks, colonies with
typical stem cell morphology were observed (Fig. 1A). Colonies were
expanded on feeders for 3 passages and then adapted to Matrigel and
chemically defined medium. Immunofluorescent staining confirmed the
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nuclear expression of the stemness markers OCT4, SOX2, and SSEA4
(Fig. 1B). The levels of OCT4, SOX2 and NANOG were confirmed si-
milar to those of the embryonic stem cell line H9 (Fig. 1C). The derived
iPSCs displayed normal karyotype at passage 6 on feeder-free condi-
tions (Fig. 1D). The differentiation potential was evaluated with the
TaqMan hPSC Scorecard Panel assay, which confirmed the pluripotency
of the transgene-free iPSCs and its ability to differentiate into the three
germinal layers (Fig. 1E). A short tandem repeat (STR) profile of 16
markers demonstrated that the 15CA cell-line matched the parental
PBMCs. Furthermore, the 15CA iPSCs were able to differentiate into
endothelial cells (Fig. 1F), astrocytes, and neurons (Fig. 1G) demon-
strating their capacity to be used in comparative studies with iPSCs
harvesting mutations in the PDCD10 gene.
4. Materials and methods
4.1. Cell culture
The 15CA cell line was derived from peripheral blood mononuclear
cells (PBMCs) from a 13-year old female. The PBMCs were isolated from
10 mL of whole blood collected in 3.2% Sodium Citrate. Erythroblast
expansion and reprogramming was performed as described in Yang
et al. (2008-2012). After passage 3 on feeders, iPSCs were plated onto
Matrigel-coated dishes (Corning, 354277) and transition to StemFlex
medium (Thermo Fisher, A3349401) following a 5-day schedule. Es-
tablished 15CA iPSCs were culture on Matrigel with daily medium
changes. EDTA buffer was used to passage cells every 5–7, days de-
pending on cell confluence. The split ratio was 1:6, and 10 μM Y27632
(Peprotech, 1293823) was added to the medium at the time of passage.
Cells were maintained at 37 °C and 5% CO2.
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Visual record of the line: normal Fig. 1 panel A
Phenotype Qualitative analysis Assess staining/expression of pluripotency
markers: OCT4 and SSEA4
Fig. 1 panel B
Quantitative analysis RT-qPCR) OCT4, SOX2 and NANOG 99% relative to H9
hES
TaqMan hPSC Scorecard panel
Fig. 1 panel C and E
Genotype Karyotype (G-banding) and resolution E.g. 46XX, Resolution 450–500 Fig. 1 panel D
Identity Microsatellite PCR (mPCR) OR
STR analysis
DNA Profiling e.g. Performed/not performed Not performed
16 sites tested, all matched Submitted in archive with
journal
Mutation analysis (IF APPLICABLE) Sequencing heterozygous/homozygous, type of mutation N/A
Southern Blot OR WGS e.g. number of insertions in genome, off-target
effects
N/A
Microbiology and virology Mycoplasma Mycoplasma testing by RT-PCR. Negative Available with authors
Differentiation potential e.g. Embryoid body formation OR Teratoma formation OR
Scorecard OR Directed differentiation
TaqMan hPSC Scorecard panel Fig. 1 panel E
Donor screening (OPTIONAL) HIV 1 + 2, Hepatitis B, Hepatitis C Negative/Positive Not performed
Genotype additional info
(OPTIONAL)
Blood group genotyping DNA analysis e.g. AA Not performed
HLA tissue typing HLA typed Class I and Class II Not performed
Fig. 1.
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4.2. RNA extraction and qPCR for stemness and pluripotency
RNA was extracted using the PureLink RNA Mini Kit (Invitrogen,
12183018A), and retro-transcribed by the High Capacity cDNA Reverse
Transcription Kit (Applied biosystems, 4368814) according to the
manufacture’s protocols. Undifferentiated and differentiated iPSCs
were tested for stemness and differentiation capabilities by RT-qPCR.
Samples were run on TaqMan® hPSC Scorecard™ Panel, (ThermoFisher
Scientific, A15872/A15870) following the manufacturer’s protocol and
analyzed online at https://apps.thermofisher.com/hPSCscorecard/
home.htm.
4.3. G-banding karyotyping
G-banding karyotyping of 15CA at passage 6 on feeder-free condi-
tions was performed by Karyologic Inc. Twenty randomly selected
metaphases were counted.
4.4. Immunofluorescence
Differentiated cells were plated on Matrigel or fibronectin coated
coverslips. After 24 or 48 h, cells were fixed with 4% formaldehyde for
15 min and permeabilized with 0.3% Triton-X for 15 min if needed.
Coverslips were blocked with 5% BSA at room temperature for 2 h.
Primary antibodies were diluted in 1% BSA in PBS and incubated
overnight at 4 degrees. Next day, cells were washed five times for 2 min
each with 0.1% Triton-X diluted in PBS, then the cells were incubated
with the corresponding secondary antibody at dilutions indicated in
Table 2 for 1 h at room temperature. Then cells were washed again five
times for 2 min each. The nucleus was contrastained with DAPI. Slides
were mounted with Fluorsave Mounting medium (Milipore Sigma, Cat#
345789) and viewed under an Evos Auto Fl microscope.
4.5. Short tandem repeat (STR) analysis
Genomic DNA was extracted from 15CA PBMCs and iPSCs using the
PureLink™ Genomic DNA Kit (Invitrogen, K182002). The STR analysis
of 16 human loci was performed by LabCorp. The authentication of cell
lines was confirmed by 16 matching loci.
4.6. Trilineage differentiation assay
15CA iPSCs were differentiated into the three germ layers using the
StemDiff Trilineage Differentiation kit (StemCell technologies, Cat #
05230). The kit include specialized media to induce in a week direct
differentiation to ectoderm, mesoderm, and endoderm. 15CA iPSCs
were collected with 0.5 mM EDTA solution and plated on 24-well plates
following the monolayer protocol recommended by the manufacture.
Differentiated cells in mesoderm and endoderm medium were collected
at day 5, and ectoderm at day 7 in the PureLink RNA (ThermoFisher
Scientific, Cat# 12183018A). Collected cells were pooled to assess
differentiation potential using the TaqMan® hPSC Scorecard™ Panel.
4.7. Endothelial differentiation
15CA iPSCs were differentiated into endothelial cells as described in
Patsch et al. (2014). Briefly, cells were collected with Accutase (Milli-
pore, Burlington, MA), and 2x10^5 cells/well plated on Matrigel coated
dishes in Stemflex (ThermoFisher Scientific, Cat#A3349401) supple-
mented with 10 µM Y27632. After 24 hrs, mesoderm fate was induced
with Priming Medium (DMEM/F12, N2, B27, Glutamax, 8 µM
CHIR99021, and 25 ng/mL BMP4). After 72 hrs, medium was changed
to differentiation medium (Stempro-34, 200 ng/mL VEGF-A and 2 µM
forskolin). At day 6, cells 2x10^5 cells/well were plated on Fibronectin
coated dishes in Expansion Medium (Stempro 34 + 50 ng/mL VEGF-A).
From this point forward, medium was changed every other day. Cells
were fixed at day 10, and stained for the endothelial-specific marker
CDH5 (VE-Cadherin).
4.8. Astrocyte differentiation
15CA iPSCs were differentiated into astrocytes as described in
Battaglia et al. (2019). Briefly, iPSCs were collected with 0.5 mM EDTA
dissociation solution, and 3 × 10 cells were seeded in one well of an
Aggrewell 800 plate (StemCell Technologies) in Neural Induction
Medium (NIM, StemCell Technologies) supplemented with 10 µM
Y27632 (Peprotech). Seventy percent of the medium was changed every
day for five days. Then, embryoid bodies (EBs) were plated on poly-
ornithine and laminin (PLO/LAM) coated dishes in NIM for 7 days. At
day 12, neural rosettes were collected using Rosette Selection Reagent
(StemCell Technologies), plated in PLO/LAM dishes, and culture in
Neural Progenitor Medium (StemCell Technologies) for another 7 days.
For astrocyte differentiation, neural progenitors were collected with
Accutase, and 1 × 10 cells/cm2 plated on PLO/LAM dishes in STEMdiff
astrocyte differentiation medium (StemCell Technologies). Astrocyte
precursors were passaged every week. At day 53, astrocytes were fixed
and stained for the astrocyte-specific marker Glial fibrillary acidic
protein (GFAP), and the neuronal marker β3 tubulin.
Table 2
Reagents details.
Antibodies used for immunocytochemistry/flow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Rabbit anti-OCT4 1:500 Abcam Cat# ab19857, RRID: AB_445175
Rabbit anti-SOX2 1:500 Abcam Cat# ab97959, RRID: AB_2341193
Mouse anti-SSEA4 1:200 Thermo Fisher Scientific Cat# MA1-021, AB_2536687
Mouse anti-TRA-1–60 1:1000 Invitrogen Cat# 41-1000 RRID: AB_2533494
Differentiation Markers CDH5 1:500 BioLegend, Cat# 348502, AB_10588267
GFAP 1:500 Sigma-Aldrich Cat#G3893, RRID: AB_477010
B3 Tubulin 1:1000 Sigma-Aldrich Cat# T5168, RRID: AB_477579
Secondary antibodies Goat Anti-rabbit IgG A594 1:1000 Thermo Fisher Scientific Cat# R37117, RRID: AB_2556545
Goat Anti-Mouse IgG A488 1:1000 Invitrogen Cat# A11001 RRID AB_2534069
Primers
Target Forward/Reverse primer (5′-3′)
Pluripotency Markers (qPCR) OCT4 Hs03005111_g1
NANOG Hs02387400_g1
SOX2 Hs01053049_s1
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4.9. Mycoplasma test
Mycoplasma detection was performed routinely by PCR using the
Universal Mycoplasma Detection Kit (ATCC, 30-1012) following man-
ufacturer’s protocol.
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